MB
MIRM icon

MPM BioImpact’s Mirum Pharmaceuticals MIRM Stock Holding History

MPM BioImpact’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-589,579
Closed -$24.4M – 50
2024
Q4 		$24.4M Buy
589,579
+96,856
+20% +$4.04M 3.46% 6
2024
Q3 		$19.2M Buy
492,723
+154
+0% +$6.14K 2.88% 10
2024
Q2 		$16.8M Buy
+492,569
New +$12.9M 2.62% 9
2022
Q4 		– Sell
-97,322
Closed -$2.04M – 40
2022
Q3 		$2.04M Sell
97,322
-191,209
-66% -$4.6M 0.48% 32
2022
Q2 		$5.62M Hold
288,531
– – 1.56% 18
2022
Q1 		$6.35M Sell
288,531
-10,321
-3% -$211K 1.71% 17
2021
Q4 		$4.77M Sell
298,852
-9,680
-3% -$151K 0.87% 26
2021
Q3 		$6.15M Buy
+308,532
New +$5.02M 0.95% 23

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MPM BioImpact's MIRM Position: Q1 2025 in Review

MPM BioImpact sold out of Mirum Pharmaceuticals (MIRM) in Q1 2025, closing a stake of 589,579 shares — an estimated $24.4M sold.

MPM BioImpact first reported a position in MIRM in Q3 2021 and held it in 8 quarters. The position peaked at $24.4M in Q4 2024. 214 funds tracked by Wall St. Rank hold MIRM as of Q1 2025.

  • MPM BioImpact reported no remaining Mirum Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • MPM BioImpact sold 589,579 Mirum Pharmaceuticals shares in Q1 2025, an estimated $24.4M.
  • MPM BioImpact first reported a position in Mirum Pharmaceuticals in Q3 2021 and held it in 8 quarters.
  • MPM BioImpact's Mirum Pharmaceuticals position peaked at $24.4M in Q4 2024.
  • 214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2025.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.